Inclusion Criteria:

- A history of prostate cancer (T1-T2-T3 N0 M0), confirmed through histopathology and
initially treated with radiotherapy.

- Biochemical failure due to Phoenix criteria (nadir + 2) and local recurrence of the
initial prostate cancer, confirmed by prostate biopsy, with neither regional
involvement nor distant metastases.

- Late local recurrence of the initial prostate cancer. A recurrence is late when it
appears after longer than 18 months post- radiotherapy.

- PSA < 10 ng/ml at the time of recurrence.

Exclusion Criteria:

- Evidence of metastatic disease.

- Previous evidence of hormone-resistant cancer.

- Patients currently receiving or having received either Luteinizing hormone-releasing
hormone (LH-RH) agonists, or antagonists, over the last 12 months.

- Patients with known hypersensitivity to triptorelin, LH-RH, other LH-RH-analogous
agonists, or any of triptorelin 22.5 mg's excipients.